Depression is prevalent among patients with axial spondyloarthritis and correlates with more severe disease activity, according to a detailed review of literature. The study, “The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis,” was published in the…
More than 700 medical experts, pharmaceutical executives, patient advocates, and others are expected to converge on Washington, D.C., next month for the 2018 NORD Rare Diseases & Orphan Products Breakthrough Summit. The Oct. 15-16 event, sponsored by the National Organization for Rare Diseases (NORD), takes place at the…
TNF-α inhibitors have the potential to prevent heart disease among patients with ankylosing spondylitis (AS) by improving blood flow in small blood vessels, researchers suggest. Their study, “Microvascular dysfunction in ankylosing spondylitis is associated with disease activity and is improved by anti-TNF treatment,” was published in the…
Poorer heart and lung function appears to be related to an increased risk of cardiovascular disease in people with ankylosing spondylitis, reported a study that suggested more aerobic exercises might be a way of improving patients’ cardiovascular fitness. The research, “Association between cardiorespiratory fitness and arterial stiffness in ankylosing…
Filgotinib, an investigational therapy for ankylosing spondylitis, was able to significantly reduce disease activity, according to recent Phase 2 study results announced by Gilead Sciences and Galapagos biotech companies. The TORTUGA trial reached its primary efficacy endpoint,…
Patients with ankylosing spondylitis have differences in the diversity of the fungi and bacterial populations that reside in the gut compared with healthy individuals, a study shows. The study, “Altered Bacteria-Fungi Inter-Kingdom Network in Gut of Ankylosing Spondylitis Patients,” was published in the journal bioRxiv. While the…
Anti-TNF therapy and other biologics — often used for the treatment of inflammatory arthritis — partially protect ankylosing spondylitis patients from heart disease, according to Australian researchers. Their study, “Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study,” was published the journal Arthritis Research…
British Columbia is now reimbursing ankylosing spondylitis treatment Renflexis (infliximab-abda) under its public drug plan, according to Merck Canada. Besides adults with ankylosing spondylitis, the reimbursement — effective Aug. 21 — covers all other approved indications. Those include treatment of adult patients with rheumatoid arthritis, psoriatic arthritis…
Izana Bioscience has launched a proof-of-concept Phase 2 clinical study to assess the efficacy of namilumab in patients with moderately to severely active ankylosing spondylitis. The trial is currently recruiting at sites across the U.K., and first results are expected by early 2019. Ankylosing spondylitis is a debilitating type of…
A pilot study will investigate how Cosentyx (secukinumab), which has been approved for some autoimmune disorders, affects bone health in patients with ankylosing spondylitis (AS). The upcoming study — titled “The Effects of Secukinumab on Bone Health and Metabolism” — is currently recruiting and will look at the effects of Cosentyx…
Get regular updates to your inbox.